The marrow stem cell: The continuum

Bone Marrow Transplantation

Volumn 32, Issue , 2003, Pages S19-S22

  Quesenberry, P J ^a   Colvin, G A ^a   Abedi, M ^a   Lambert, J F ^a   Moore, B ^a   Demers, D ^a   Greer, D ^a   McAuliffe, C ^a   Dooner, M ^a   Lum, L G ^a   Badiavas, E ^a   Falanga, V ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Progenition cell cycle; Stem cell

Indexed keywords

CYTOKINE; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6; STEEL FACTOR; THROMBOPOIETIN;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; CELL PROLIFERATION; CELL STRUCTURE; CELL TYPE; CHIMERA; GENE THERAPY; GROWTH STIMULATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PLASTICITY; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

ANIMALS; BONE MARROW CELLS; CELL CYCLE; CELL DIFFERENTIATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; PLURIPOTENT STEM CELLS;

EID: 10744229835     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703938     Document Type: Article

References (27)

1. Quesenberry PJ, Stewart FM, Becker P et al. In: Orlic D, Brummendorf TH, Sharkis SJ, Kanz L, (eds). Stem Cell Engraftment Strategies in Hematopoietic Stem Cells 2000: Basic and clinical sciences, Third International, Vol. 938; New York Academy of Sciences: New York, 2001; in press.
2. Rao SS, Peters SO, Crittenden RB et al. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol 1997; 25: 114-121.
3. Stewart FM, ZhongS, Wuu J et al. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 1998; 91: 3681-3687.
4. Micklem HS, Clarke CM, Evans EP, Ford CE. Fate of chromosome-marked mouse bone marrow cells transfused into normal syngeneic recipients. Transplantation 1968; 6: 299.
5. Brecher G, Ansell JD, Micklem HS et al. Special proliferative sites are not needed for seedingand proliferation of transfused bone marrow cells in normal syngeneic mice. Proc Natl Acad Sci USA 1982; 79: 5085.
6. Quesenberry PJ, ZhongS, Wang H, Stewart FM. Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice. Blood 2001; 97: 557-564.
7. Lambert JF, Colvin GA, Zhong S et al. H2 mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation. Br J Hematol 2002; 119: 155-163.
8. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
9. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graftversus-tumor effects. Blood, 2001; 97: 3390-3400.
10. Khouri IF, KeatingM, KörblingM et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitorcell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
11. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 1998; 91: 756-763.
12. Ballen K, Becker P, Emmons R et al. Low dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 2002; 100: 442-450.
13. Colvin G, Lambert JF, Lum L et al. Universal immunotherapeutic approach for patients with refractory malignancies: HLA-haploidentical transplants in 100 cGy-conditioned hosts. Exp Hematol 2002; 30: 110 (abstract).
14. Kittler EL, Peters SO, Crittenden RB et al. Cytokinefacilitated transduction leads to low-level engraftment in non-ablated hosts. Blood, 1997; 90: 865-872.
15. Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ. Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol 1995; 23: 461-469.
16. Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ. Ex vivo expansion of murine marrow cells with interleukin-3, interleukin-6, interleukin-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 1996; 87: 30-37.
17. Reddy GP, Tiarks CY, PangL et al. Cell cycle analysis and synchronization of pluripotent hematopoietic progenitor stem cells. Blood 1997; 90: 2293-2299.
18. Habibian HK, Peters SO, Hsieh CC et al. The fluctuating phenotype of the lympho-hematopoietic stem cell with cell cycle transit. J Exp Med 1998; 188: 393-398.
19. Lambert JF, Liu M, Baskaran NV et al. Purified hematopoietic stem cells show a major shift of gene expression through cell cycle that coincides with an engraftment nadir. Exp Hematol 2002; 30: 118 (abstract).
20. Becker PS, Nilsson SK, Li Z et al. Adhesion receptor expression by hematopoietic cell lines and murine progenitors: modulation by cytokines and cell cycle status. Exp Hematol 1999; 27: 533-541.
21. Berrios VM, Dooner GJ, Nowakowski G et al. The molecular basis for the cytokine-induced defect in horningand engraftment of hematopoietic stem cells. Exp Hematol 2001; 29: 1326-1335.
22. Frimberger A, McAuliffe CI, Werme KA et al. The fleet feet of hematopoietic stem cells: rapid motility, interaction and proteopedia. Br J Haematol 2001; 112: 644-654.
23. Colvin G, Lambert JF, McAuliffe C, Quesenberry PJ. Stem/progenitor cell inversions: the Chiaroscuro stem cell model of hematopoiesis. Exp Hematol 2002; 30: 128 (abstract).
24. Cerny J, Dooner M, McAuliffe C et al. Homingof purified murine lymphohematopoietic stem cells: a cytokineinduced defect. J Hematother & Stem Cell Res 2002; 11: 913-922.
25. Nilsson SK, Dooner MS, Weier HU et al. Cells capable of bone production engraft from whole bone marrow transplants in nonablated mice. J Exp Med 1999; 189: 729-734.
26. Abedi M, Colvin G, Lambert JF et al. Green fluorescent protein (GFP) positive marrow traffickingto injured murine liver. Exp Hematol 2002; 30(1): 128 (abstract).
27. Abedi M, Badiavas E, Lambert JF et al. Traffickingand transdifferentiation of bone marrow cells in a skin injury model. Exp Hematol 2002; 30: 47 (abstract).